Abstract:Management of patients with aortic dissection includes medical and surgical treatments. Because of the high surgical morbidity and mortality rate, transluminal stent graft placement (TSGP) has emerged as a new treatment instead of open surgery for aortic dissection of a descending aortic intimal tear.1 In our institute, we use TSGP to seal the entry site for both acute onset and chronic Standford B type aortic dissections. The implantation technique and outcome of this treatment are discussed. CLINICAL DATA Patients Between March 2003 and March 2006, 28 patients with type B aortic dissection, 23 men and 5 women, underwent TSGP. The table shows the baseline demographics and clinical characteristics of these patients. Patients were followed for 4 to 38 months, and the mean followup duration was (16.6 + 9.7) months. Contrast enhanced spiral CT (n=9) or MRI (n=19) was taken to obtain the anatomical characteristics of the patients. The diameter of normal part of descending aorta was (30.2±7.3) mm with range from 26 to 34 mm; of proximal part of true lumen (26.1±8.2) mm with range from 21 to 35 mm and of distal part (15.3±9.4) mm with range from 8 to 26 mm. Distance from left subclavian artery to entry site was (26.6±9.2) mm with rangefrom 10 to 45 mm. The number of entry sites was 2.42±1.44 (range, 1 to 6).Table: Demographics and characteristics of patients undergoing transluminal stent graft placement for aortic dissectionStent graft placement The stent graft procedures have been described in detail in Dake's report.2 Briefly, all implantations were performed under general anaesthesia with tracheal intubation. Aortography was done via a left subclavian artery with a 5-F pigtails catheter for precise guidance near the subclavian artery and for intraprocedural aortography. Aortography was performed before and after the stent graft deployment to confirm the location of the stent graft, the absence of perigraft leakage and the patency of adjacent branch vessels. When the position of the wire in the true lumen of the aorta had been confirmed by fluoroscopy, the sheath with the stent and a deflated, large bore, latex balloon was introduced. The stent was expanded by inflation of balloon at 203–304 kPa. To ensure optimal positioning, care was taken to seal the entry with stent and to protect the left subclavian artery with the bare spring end of the stent. Followup analysis Followup CT performed within one week of the stent graft implantation determined the extent of thrombosis in the aortic false lumen, the size of the true and false lumens, the blood perfusion to the branch vessels and the position and shape of stent graft. Clinical information was compiled by two followup doctors by phone call and outpatient office interview. Statistical analysis Clinically important rates are reported with 95% confidence interval (95% CI), and continuous variables are expressed as means ± standard deviation (SD). SPSS 11.0 was used for statistical analysis. RESULTS Procedural success TSGP was technically successful in 27 patients (96.4%) and no one died during the operation. One patient was given percutaneous surgery because the catheter cannot pass through the aortic true lumen. Sealing of the primary entry tear was monitored during the procedure by angiography and was successful in twenty-three patients immediately after the TSGP. Four patients had early type I endoleak through the proximal attachment site: two did not attend any followup; of them disappeared after replacement of stents. The other two attended first disappeared in the followup. The orifice of the left subclavian artery was occluded in two patients during the TSGP (Figs. 1, 2). There were two stent graft migrations and no stent graft torsion or folding in any patient. No patient required blood transfusion or inotropic support. Thirty eight stent grafts were used.Fig. 1.: Aortography via a left subclavian artery with a 5-F pigtails catheter showing that primary entry tear located less than 10 mm distal to the orifice of the left subclavian artery.Fig. 2. Aortography via the left subclavian artery with a 5-F pigtails catheter showing that orifice of left subclavian artery had been occluded by the stent graft.Early results of stent graft One patient died of putrescence of mesenteric arterial embolism on the fifth day after operation with a mortality of 3.6% (95% CI 0 to 10.9%). Two patients experienced abdominal aortic dissection after TSGP (7.2%; 95% CI 0 to 17.4%) and one of them underwent TSGP again. There was not any renal insufficiency, heart failure, paraplegia or paralysis. Transient postimplantation syndrome with mild leukocytosis and moderately elevated body temperature occurred in 10 of the 28 patients. Thrombosis of aortic false lumen and enlargement of true lumen were revealed on CT in 27 patients. There was no migration and no stent graft torsion or folding during followup. The only minor complication was one superficial wound infection. Later results of stent graft During the followup of 4 to 38 months, 27 patients were well without having suffered aortic rupture, organ or limb ischaemia. At three months, there was clear evidence of expansion of the true lumen and shrinkage of the false lumen as a result of consolidation of thrombosis in all patients suggesting that the aortic tube had been remodelled with enlargement of the reconstructed true lumen. All the patients resumed an active life, all of them received on antihypertensive medication and none was readmitted to the hospital. Actuarial survival rate and cardiovascular event free rate were 96.4% (95% CI 89.1% to100%) and 100% overall after procedure at last followup. DISCUSSION Since Dake et al2 reported the feasibility of endovascular stent grafting of descending thoracic aneurysms in 1994, some clinical experiences using TSGP for descending aortic disease have been reported.3 The results showed that the effectiveness of the treatment was very encouraging, and there were only a few complications. However, the surgical mortality and morbidity rate are still around 20% to 60%.4 Based on this experience, we ran a clinical trial of TSGP sealing the primary entry site in the descending thoracic aorta, not only in chronic aortic dissection, but also in three cases of acute onset. In our study, TSGP was successful in 27 patients There was no renal insufficiency, no heart failure, no paraplegia or paralysis. No one died in operation. Actuarial survival rate and cardiovascular event-free rate were 96.4% and 100% overall after procedure at last followup. Our data suggest that TSGP is an attractive treatment option for aortic dissection. Type I endoleaks are the most frequent complication of stent graft treatment of aortic dissection, which could be a potential progression of the dissection during followup.5,6 In our series, 4 of 28 patients (14.3%) had early type I endoleak through the proximal attachment site. For type I endoleaks, we recommend regular followup imaging studies to see if there is any change in the dissected false lumen. Until an overt enlargement of the false lumen is detected, surgical management can be suggested. Many different experiences showed that the incidence of spinal cord ischaemic complications was 7% to 35% of cases relative to intercostal artery sacrifice and aortic clamping during open repair.7,8 We have not experienced any cases of neurological complications in our patients. The correct deployment far from vertebrae T8 to L2 can minimize the risk of paraplegia. Furthermore, the stent graft procedure took a short time without circulatory arrest and crossclamping of the aorta or associated ischaemia and reperfusion injury. It averted postoperative respiratory failure and prolonged hypotension and the associated risk of delayed paraplegia. Furthermore, in the case of aneurysms, many intercostals branches are already occluded and the spinal cord is perfused by collaterals. The sudden deployment of the stent graft, followed by the occlusion of the intercostal branches, does not produce Steal syndrome in the perfusion of the spinal cord. With the use of TSGP in our study, the aorta was reconstructed with an excellent outcome and without the need for complex protective measures. Gentle manoeuvring of the guide wire and introducer could be the only way to lower the incidence of cerebral embolic complications. Correct location was based on the thoughtful analysis of the result of angiography and judgement of extent of true lumen. Aortic angiography by a 5-F pigtails catheter from abdominal aorta to aortic route and by another 5-F pigtails catheter via a left subclavian artery should combine together for precise guidance. Nienaber 9 suggested that a primary entry tear located at least 10 mm distal to the orifice of the left subclavian artery to avoid the influence of blood supply of the left subcalvian artery. Among the patients with tears located at least 10 mm distal to the orifice, existence of entry tear located at small curvature of aortic arch shows high risk of endoleak. But many dissections have primary entry tears close to the orifices of the left subclavian arteries. We intentionally occluded orifice of left subclavian artery in two cases with the stent graft but they did not show ischaemia of their upper extremities or brain. It shows that the stent graft is a choice even for the patients with a primary entry tear located less than 10 mm distal to the orifice of the left subclavian artery. In conclusion, TSGP is an efficient and safe modality for the treatment of type aortic dissection. However, various problems and complications could occur during the procedure and followup period. Thorough evaluation of preoperative imaging scans, meticulous procedure and close followup are mandatory to minimise such problems. Although initial results of TSGP of type B dissection are promising, the concept of nonsurgical management needs vindication by long term followup data.

Abstract:Once the ascending aorta gets involved and however farther the dissection extends, it is named type A dissection (TAD), in which the entry tear usually locates in the ascending aorta. But there exists a small subset with primary entry tear in the descending aorta and the dissection process extends back into the ascending aorta, which here we name primary retrograde type A dissection (PRTAD). Operative procedures are far more difficult and extensive for PRTAD and usually result in poor prognosis in the aspects of surgical mortality and survival rate during follow-up.1–3 Kato et al4 and Chang et al5 showed successful method of endovascular repair for PRTAD and recommended it as an alternative to the operative treatment. During March 2008 to August 2010, five continuous patients with PRTAD were admitted into our institution. We here introduce our preliminary experience with medical therapy and thoracic endovascular aortic repair (TEVAR) for treating PRTAD. METHODS Patient selection and demographics Inclusion criteria: (1) TAD with primary entry tear in the descending aorta; (2) no signs of cardiac tamponade or severe aortic regurgitation; (3) no signs of ischemia of the coronary artery or arch branches. Between March 2008 and August 2010, totally 359 patients of type B dissection were admitted into our institution all diagnosed by computed tomographic angiography (CTA), mostly from various hospitals throughout China. We rearranged CTA for each patient and found that seven patients were eventually TAD: one patient with the entry tear in the ascending aorta complicating by lesions of three main coronary arteries, and the remaining six patients were actually PRTAD: one patient had uncontrollable chest pain and impending aortic rupture, and was referred to Department of Cardiac Surgery for emergent surgical aortic repair. Finally, the remaining five patients all got stabilized with medical therapy initially. Detailed demographics such as patient age, gender, comorbidity and the phase of dissection were collected. Treatment strategy and stent graft placement Once vitals were stabilized, further treatment was applied, either simply medically or additionally by TEVAR. Medical therapy was composed of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcium antagonists administrated alone or in combination. Close observation was managed to maintain the systolic blood pressure of less than 140 mmHg. The endovascular procedure has been described in detail elsewhere.6 Important aspects potentially associated with PRTAD are highlighted as follows. Oversizing rate was between 10%-15% according to aortic diameter of proximal anchoring site (including both the true lumen and the false lumen). If the proximal landing zone, the distance from the origin of left subclavian artery (LSA) to primary entry site, was less than 15 mm, coverage of LSA was intentionally applied in order to create an extra anchoring area. Stent graft system There were three types of stent graft systems used in the study, including Hercules (Microport, China), Valiant (Medtronic, USA), and Zenith TX2 (Cook, USA), with the graft ranging from 150 to 160 mm in length and from 38 to 40 mm in diameter. Follow-up protocol and data collection All the patients were followed up by CTA at 1, 3, and 6 months and yearly thereafter after treatment. The diameter of the aorta is reported as mean±standard deviation. All the statistics of patient information and aortic diameter measurements from every CTA were collected by the author. RESULTS Patient demographics and characteristics Among the five PRTAD patients, three were male and two female, with mean age of (60±16) years (range, 36-85 years); three were in the acute phase, one in the subacute phase, and one in the chronic phase. The acute phase was defined as within 2 weeks after symptom onset, and the subacute phase was the following 2-month period; with anything thereafter called the chronic phase. Detailed patient demographics and clinical characteristics were listed in Table 1.Table 1: Patient demographics and clinical charateristicsTreatment strategy Once blood pressure got stabilized and fully considered all the patients' conditions, we continued medical therapy for patient 4 because of advanced age and malignant tumor resulting in short life expectancy and patient 5 for financial reasons. Patient 1, patient 2, and patient 3 underwent TEVAR at last (Table 1). Immediate outcomes of TEVAR Technical success was achieved in all 3 TEVAR cases. In order to acquire adequate proximal landing zone, LSA was intentionally covered in patient 2 and partially covered in patient 1, in whom proximal type I endoleak was detected on the completion angiogram and significantly resolved after a quick gentle ballooning. No procedure-related complications occurred. Follow-up outcomes All patients (patients 1-5) were followed up with an average period of (4.6±2.7) months (range, 1-11 months), and free from procedure-related complications. CTA images revealed neither edema around ascending aorta and aortic arch, nor new entry at either end of the stent graft. The false lumen was completely thrombosed in patient 1, patient 3, and patient 5, and partially thrombosed in patient 2 and patient 4. Table 2 showed the aorta diameter measurement before and after treatment in the segment of ascending aorta, aortic arch, aorta of the anchoring site, and true lumen of the descending aorta. Mean diameter before treatment was (38.4±7.4), (30.0±7.1), (33.3±2.3), and (34.0±8.1) mm, respectively. According to the latest follow-up CTA, there was slight enlargement of the ascending aorta, aortic arch, and aorta of the anchoring site which reached (40.4±4.3), (33.4±3.8), and (38.0±1.7) mm, respectively; however, the true lumen of descending aorta remained relatively stable, (33.9±6.5) mm (Figure 1). The average diameter of ascending aorta, aortic arch, and the anchoring site of the TEVAR patients increased by 3.7, 5.3, and 4.7 mm respectively (Table 2). Meanwhile, mean diameter of the descending aorta decreased by 4.0 mm, which may be caused by thrombosis of the false lumen. The aorta segment of diaphragm expanded slightly by 1.3 mm. On the contrary, aorta remodeling of patients with medical therapy seemed different. The mean diameter of ascending aorta and aortic arch showed no obvious change, while that of descending aorta and segment of diaphragm expanded slightly by 3.5 and 5.5 mm, respectively.Table 2: Diameter measurement of CTA images of TEVAR and medical therapy (mm)Figure 1.: CTA images of patient 3 with TEVAR, the preoperative CTA showing the primary tear located immediately distal to LSA with thrombosed false lumen at the aortic arch and an intact ascending aorta (A, B), follow-up CTA at 3 months demostrating the complete false lumen thrombosis, the satisfactory aortic remodeling, and freedom from new-onset dissection or aneurysmal dilation (C, D).DISCUSSION In our center, PRTAD approximately stood for 1.7 % (6/358) of all the type B dissection. As far as we know, there existed controversies on its optimal treatment, and reports in this regard were rare. In this study, we discussed our acceptable preliminary experience of treating PRTAD with TEVAR and medical therapy as well. The rationale for TEVAR for PRTAD lays great emphasis on complete entry closure in the descending aorta and subsequent complete thrombosis of false lumen, which is almost similar to that for type B dissection. Kato et al4 and Chang et al5 have already showed successful experience in treating PRTAD with stent-graft placement and recommended it as an alternative to the surgical treatment. In our study, CTA images of all patients showed a predominant distal dissection in the discending aorta, with almost intact, thrombosed, and relatively small ascending aorta and aortic arch. Meanwhile, all the patients were stabilized with initial medical therapy. Given potential risks associated with the surgical aortic replacement, TEVAR was considered a reasonable alternative. TEVAR was ultimately applied to three patients. On the other hand, there were some TEVAR-specific concerns in patients with PRTAD: if such fragile and dissected proximal landing zone sustain the radial force of the stent-graft, and if the proximal fixation device of the endograft, such as bards of Zenith TX2 and the bare spring of Valiant, yields newly developed dissection or even aortic rupture. Ultimately, all three cases recovered uneventfully from TEVAR and remained free from dissection- or TEVAR-related complications during the follow-up. Compared to the usual type B dissection, PRTAD was characteristic of an unhealthy proximal landing zone, which resultantly posed the great concern of whether TEVAR would increase the risk of stent-graft-induced new entry. According to Dong et al,7 the incidence of stent-graft-induced new entry reached 3.4%, which were 22 out of 650 patients after TEVAR for type B dissection. And, the underlying causes for this complication included spring-back force from the passively curved stent graft when placed across the aortic arch potential injury of its proximal bare stent or barbs, and its radial force as well. The former two causes highly associated with the material property and design of the stent graft, which are impractical to be changed overnight. As for the radial force, however, it could be put under control via an appropriate stent graft oversizing by doctors during the pre-procedural evaluation. Therefore, in order to minimize the radial-force-induced injury, we used the diameter of the whole aorta including both the true and false lumina as the baseline for oversizing of the stent graft. Ultimately, there was no development of stent-graft-induced new entry in all TEVAR cases, suggesting the safety and feasibility of TEVAR for PRTAD. To date, medical therapy remains the first choice for uncomplicated type B dissection. Medical therapy should also be recommended for PRTAD due to its primary entry site in the descending aorta, in the setting of an intact ascending aorta with a thrombosed false lumen and no aneurysmal dilation. For the two medically treated cases in the current study, partial and complete false lumen thrombosis of the thoracic aorta were evidenced on follow-up CTA at 1 and 5 months, respectively, consistent with the fact that the simple medical treatment could also yield satisfactory outcomes. Nevertheless, CTA identified enlargement of the descending thoracic aorta in them during the follow-up, indicating relatively poorer aortic remodeling after the mere medical management. As was known, continuous aneurysmal dilation of aorta was responsible for the main stream of dissection related death due to the resultant lethal aortic rupture. Furthermore, though more than 90% of patients with uncomplicated type B dissection could luckily survive with medical therapy alone, it was unfortunately not so in terms of the three-year survival rate, which decreased to 78%, and the 5-year survival rate after firstly diagnosed was dramatically low ranging from 48% to 82%. Therefore, medical therapy alone could only be recommended in highly selected patients with serious comorbidities and short life expectancy.

Transluminal Stent Graft Placements for the Treatment of Standford B Type Aortic Dissection

Endoluminal and Surgical Treatment for the Management of Stanford Type A Aortic Dissection.

Endovascular Stent-graft Treatment for Stanford Type A Aortic Dissection

Endovascular Repair of Retrograde Stanford Type A Aortic Dissection with a New Stented Graft.

Endovascular stent-graft treatment of thoracic aortic dissection.

Subclavian Artery Angioplasty Allows for Implantation of the in Situ Internal Thoracic Artery Graft in Patients Scheduled for Surgical Myocardial Revascularization.

Endovascular stent graft repair of aortic dissection type B extending to the aortic arch.

Review and mid-term follow-up of Stanford type B aortic dissections treated by endovascular placement of stent-grafts

Initial Study of the Extended STABILISE Technique for Complete Remodeling in Aortic Dissection

Clinical Experience of Early Anticoagulant Therapy after Endovascular Stent-Graft Exclusion for Stanford B Type Aortic

Endovascular Graft Exclusion in Treatment of Thoracic Aortic Dissection Aneurysm (stanford B): a Report of 29 Cases

Institutional report - Vascular thoracic Endovascular stent-graft treatment of thoracic aortic dissection

Outcomes of Endovascular Repair of Ascending Aortic Dissection in Patients Unsuitable for Direct Surgical Repair.

Endovascular Stent-Grafts Treatment in Acute Aortic Dissection (type B): Clinical Outcomes During Early, Late, or Chronic Phases

Endovascular therapy for stanford type B aortic dissection in 102 cases.

In situ fenestration (ISF) versus single-branched stent graft (SBSG) implantation in the management of acute Stanford type B aortic dissection involving the left subclavian artery

Experience and Early Outcome of Treating Retrograde Type A Dissection with Primary Entry Tear in the Descending Thoracic Aorta.

Application of Triple-Branched Stent Graft for Stanford Type A Aortic Dissection: Potential Risks.

Endovascular Repair for the Treatment of Stanford Type A Aortic Dissection

Endovascular Therapy for Stanford Type B Aortic Dissections: a Report of 158 Cases

Midterm Results of Prospective Study for Aortic dissection with Gutter-Plugging Chimney Stent-Graft